Detailed information for compound 346935

Basic information

Technical information
  • TDR Targets ID: 346935
  • Name: N-cyclopropyl-2-[[7-[(2R,3R,4S,5R)-3,4-dihydr oxy-5-methyloxolan-2-yl]-5-phenylpyrrolo[2,3- d]pyrimidin-4-yl]amino]acetamide
  • MW: 423.465 | Formula: C22H25N5O4
  • H donors: 4 H acceptors: 5 LogP: 1.35 Rotable bonds: 7
    Rule of 5 violations (Lipinski): 1
  • SMILES: O=C(NC1CC1)CNc1ncnc2c1c(cn2[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C)c1ccccc1
  • InChi: 1S/C22H25N5O4/c1-12-18(29)19(30)22(31-12)27-10-15(13-5-3-2-4-6-13)17-20(24-11-25-21(17)27)23-9-16(28)26-14-7-8-14/h2-6,10-12,14,18-19,22,29-30H,7-9H2,1H3,(H,26,28)(H,23,24,25)/t12-,18-,19-,22-/m1/s1
  • InChiKey: ICOXDTNKZOZKAQ-XHLLGHLISA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • N-cyclopropyl-2-[[7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyl-tetrahydrofuran-2-yl]-5-phenyl-pyrrolo[2,3-d]pyrimidin-4-yl]amino]acetamide
  • N-cyclopropyl-2-[[7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyl-2-tetrahydrofuranyl]-5-phenyl-4-pyrrolo[2,3-d]pyrimidinyl]amino]acetamide
  • N-cyclopropyl-2-[[7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyl-oxolan-2-yl]-5-phenyl-pyrrolo[2,3-d]pyrimidin-4-yl]amino]ethanamide
  • N-cyclopropyl-2-[[7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-phenylpyrrolo[3,2-e]pyrimidin-4-yl]amino]acetamide
  • N-cyclopropyl-2-[[7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyl-tetrahydrofuran-2-yl]-5-phenyl-pyrrolo[3,2-e]pyrimidin-4-yl]amino]acetamide
  • N-cyclopropyl-2-[[7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyl-2-tetrahydrofuranyl]-5-phenyl-4-pyrrolo[3,2-e]pyrimidinyl]amino]acetamide
  • N-cyclopropyl-2-[[7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyl-oxolan-2-yl]-5-phenyl-pyrrolo[3,2-e]pyrimidin-4-yl]amino]ethanamide

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens adenosine kinase Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Trypanosoma cruzi adenosine kinase, putative Get druggable targets OG5_128398 All targets in OG5_128398
Leishmania braziliensis adenosine kinase, putative Get druggable targets OG5_128398 All targets in OG5_128398
Candida albicans adenosine kinase Get druggable targets OG5_128398 All targets in OG5_128398
Onchocerca volvulus Get druggable targets OG5_128398 All targets in OG5_128398
Trypanosoma brucei adenosine kinase, putative Get druggable targets OG5_128398 All targets in OG5_128398
Loa Loa (eye worm) hypothetical protein Get druggable targets OG5_128398 All targets in OG5_128398
Trypanosoma congolense adenosine kinase, putative Get druggable targets OG5_128398 All targets in OG5_128398
Schistosoma mansoni adenosine kinase Get druggable targets OG5_128398 All targets in OG5_128398
Echinococcus multilocularis adenosine kinase Get druggable targets OG5_128398 All targets in OG5_128398
Trypanosoma brucei adenosine kinase, putative Get druggable targets OG5_128398 All targets in OG5_128398
Leishmania donovani adenosine kinase, putative Get druggable targets OG5_128398 All targets in OG5_128398
Schistosoma mansoni adenosine kinase Get druggable targets OG5_128398 All targets in OG5_128398
Neospora caninum GG10762, related Get druggable targets OG5_128398 All targets in OG5_128398
Schistosoma japonicum ko:K00856 adenosine kinase [EC2.7.1.20], putative Get druggable targets OG5_128398 All targets in OG5_128398
Leishmania infantum adenosine kinase, putative Get druggable targets OG5_128398 All targets in OG5_128398
Leishmania mexicana adenosine kinase, putative Get druggable targets OG5_128398 All targets in OG5_128398
Echinococcus granulosus adenosine kinase Get druggable targets OG5_128398 All targets in OG5_128398
Brugia malayi Adenosine kinase-like Get druggable targets OG5_128398 All targets in OG5_128398
Toxoplasma gondii kinase, pfkB family protein Get druggable targets OG5_128398 All targets in OG5_128398
Leishmania major adenosine kinase, putative Get druggable targets OG5_128398 All targets in OG5_128398
Babesia bovis adenosine kinase Get druggable targets OG5_128398 All targets in OG5_128398
Trypanosoma cruzi adenosine kinase, putative Get druggable targets OG5_128398 All targets in OG5_128398
Trypanosoma brucei gambiense adenosine kinase, putative Get druggable targets OG5_128398 All targets in OG5_128398
Candida albicans putative adenosine kinase Get druggable targets OG5_128398 All targets in OG5_128398
Trypanosoma brucei gambiense adenosine kinase, putative Get druggable targets OG5_128398 All targets in OG5_128398
Cryptosporidium parvum adenosine kinase like ribokinase Get druggable targets OG5_128398 All targets in OG5_128398
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Trypanosoma cruzi adenosine kinase, putative adenosine kinase 345 aa 337 aa 35.6 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Echinococcus multilocularis adenosine kinase 0.0105 0.0553 0.0553
Trypanosoma cruzi squalene synthase, putative 0.0567 0.5811 1
Onchocerca volvulus Phospholipase A2 homolog 0.0397 0.3881 1
Plasmodium falciparum hexose transporter 0.0057 0 0.5
Echinococcus multilocularis Squalene phytoene synthase 0.0177 0.1368 0.1368
Plasmodium vivax hexose transporter 0.0057 0 0.5
Loa Loa (eye worm) hypothetical protein 0.0105 0.0553 0.1426
Leishmania major squalene synthase, putative 0.0567 0.5811 1
Echinococcus granulosus sodium:myo inositol cotransporter 0.0934 1 1
Onchocerca volvulus 0.0238 0.2072 0.4777
Trypanosoma brucei squalene synthase, putative 0.0567 0.5811 1
Brugia malayi GH02984p 0.0238 0.2072 0.5338
Echinococcus granulosus sodium coupled monocarboxylate transporter 1 0.0238 0.2072 0.2072
Echinococcus granulosus solute carrier family 5 0.0934 1 1
Loa Loa (eye worm) hypothetical protein 0.0238 0.2072 0.5338
Mycobacterium tuberculosis Probable phytoene synthase PhyA 0.0177 0.1368 0.5
Brugia malayi Adenosine kinase-like 0.0105 0.0553 0.1426
Schistosoma mansoni inositol transporter 0.0934 1 1
Schistosoma mansoni sodium/solute symporter 0.0238 0.2072 0.2072
Toxoplasma gondii kinase, pfkB family protein 0.0105 0.0553 0.2671
Echinococcus multilocularis sodium:myo inositol cotransporter 0.0934 1 1
Loa Loa (eye worm) hypothetical protein 0.0397 0.3881 1
Echinococcus granulosus sodium:glucose cotransporter 2 0.0934 1 1
Trypanosoma cruzi phytoene synthase, putative 0.0177 0.1368 0.1549
Echinococcus granulosus high affinity choline transporter 1 0.0238 0.2072 0.2072
Brugia malayi Phospholipase A2 family protein 0.0397 0.3881 1
Toxoplasma gondii transporter, solute:sodium symporter (SSS) family protein 0.0238 0.2072 1
Echinococcus granulosus adenosine kinase 0.0105 0.0553 0.0553
Loa Loa (eye worm) hypothetical protein 0.0177 0.1368 0.3524
Echinococcus multilocularis high affinity choline transporter 1 0.0238 0.2072 0.2072
Trichomonas vaginalis conserved hypothetical protein 0.0057 0 0.5
Onchocerca volvulus Phospholipase A2 homolog 0.0397 0.3881 1
Echinococcus multilocularis sodium coupled monocarboxylate transporter 1 0.0238 0.2072 0.2072
Trypanosoma cruzi squalene synthase, putative 0.0567 0.5811 1
Onchocerca volvulus NADH dehydrogenase (ubiquinone) complex I, assembly factor 6 homolog 0.0177 0.1368 0.2745
Echinococcus multilocularis solute carrier family 5 0.0934 1 1
Echinococcus multilocularis sodium:glucose cotransporter 2 0.0934 1 1
Loa Loa (eye worm) hypothetical protein 0.0238 0.2072 0.5338
Schistosoma mansoni hypothetical protein 0.0177 0.1368 0.1368
Mycobacterium ulcerans phytoene synthase, CrtB 0.0177 0.1368 0.5
Echinococcus granulosus Squalene phytoene synthase 0.0177 0.1368 0.1368
Leishmania major hypothetical protein, conserved 0.0177 0.1368 0.1549
Schistosoma mansoni adenosine kinase 0.0105 0.0553 0.0553
Loa Loa (eye worm) hypothetical protein 0.0397 0.3881 1
Brugia malayi Sodium:solute symporter family protein 0.0238 0.2072 0.5338
Schistosoma mansoni adenosine kinase 0.0105 0.0553 0.0553
Schistosoma mansoni inositol transporter 0.0934 1 1
Schistosoma mansoni high-affinity choline transporter 0.0238 0.2072 0.2072

Activities

Activity type Activity value Assay description Source Reference
Activity (ADMET) 0 Toxicity in rat liver administered at 75 umol/kg, iv ChEMBL. 16302820
AUC (ADMET) = 981.1 ng.hr/ml AUC (0-24) in rat at 3 mg/kg, po ChEMBL. 16302820
AUC (ADMET) = 1489.5 ng.hr/ml AUC (0-24) in dog at 3 mg/kg, po ChEMBL. 16302820
CL (ADMET) = 2.1 L/hrs.kg Clearance in dog at 3 mg/kg, po ChEMBL. 16302820
CL (ADMET) = 3.4 L/hrs.kg Clearance in rat at 3 mg/kg, po ChEMBL. 16302820
Cmax (ADMET) = 517.7 hr Maximum concentration in dog at 3 mg/kg, po ChEMBL. 16302820
Cmax (ADMET) = 659.7 hr Maximum concentration in rat at 3 mg/kg, po ChEMBL. 16302820
ED50 (functional) 0 Hyperalgesia in male SD rat administered 1 hr before carageenan injection, analgesia tested at 6 hrs ChEMBL. 16302820
ED50 (functional) = 0.9 mg kg-1 Bradykinin-induced licking in male marmoset monkey ChEMBL. 16302820
ED50 (functional) = 1.6 mg kg-1 Hyperalgesia in male SD rat administered 2 hrs after carageenan injection, analgesia tested at 3 hrs ChEMBL. 16302820
ED50 (functional) = 2.5 mg kg-1 Inhibition of formalin induced paw pain in male SD rat ChEMBL. 16302820
ED50 (functional) = 2.6 mg kg-1 Hyperalgesia in male SD rat administered 1 hr before carageenan injection, analgesia tested at 3 hrs ChEMBL. 16302820
ED50 (functional) = 3.8 mg kg-1 Hyperalgesia in male SD rat administered 1 hr before carageenan injection, analgesia tested at 4 hrs ChEMBL. 16302820
ED50 (functional) = 4.1 mg kg-1 Hyperalgesia in male SD rat administered 2 hrs after carageenan injection, analgesia tested at 4 hrs ChEMBL. 16302820
ED50 (functional) = 6.5 mg kg-1 Hyperalgesia in male SD rat administered 2 hrs after carageenan injection, analgesia tested at 5 hrs ChEMBL. 16302820
ED50 (functional) = 62 mg kg-1 Rotorod test in rat at 5 hrs ChEMBL. 16302820
ED50 (functional) = 102 mg kg-1 Rotorod test in rat at 2 hrs ChEMBL. 16302820
ED50 (functional) > 300 mg kg-1 Rotorod test in rat at 0.5 hrs ChEMBL. 16302820
ED50 (functional) > 300 mg kg-1 Rotorod test in rat at 1 hr ChEMBL. 16302820
F (ADMET) = 128 % Oral bioavailability in rat at 3 mg/kg, po ChEMBL. 16302820
F (ADMET) = 278 % Oral bioavailability in dog at 3 mg/kg, po ChEMBL. 16302820
IC50 (binding) = 0.003 uM Inhibitory activity against recombinant human adenosine kinase ChEMBL. 16302820
IC50 (binding) = 0.003 uM Inhibitory activity against recombinant human adenosine kinase ChEMBL. 16302820
Inhibition (functional) < 50 % Hyperalgesia in male SD rat administered 1 hr before carageenan injection, analgesia tested at 5 hrs ChEMBL. 16302820
Inhibition (functional) < 50 % Hyperalgesia in male SD rat administered 2 hrs after carageenan injection, analgesia tested at 6 hrs ChEMBL. 16302820
Inhibition (functional) = 66 % Inhibition of the licking and biting response at 20 mg/kg, po in rat by formalin paw antinociceptive assay ChEMBL. 16302820
Solubility = 32 ug ml-1 Solubility in water at pH 7.4 ChEMBL. 16302820
T1/2 (ADMET) = 0.3 hr Half life at early phase in rat at 3 mg/kg, po ChEMBL. 16302820
T1/2 (ADMET) = 2 hr Half life in dog at 3 mg/kg, po ChEMBL. 16302820
T1/2 (ADMET) = 3.3 hr Metabolic stability by incubation with human liver microsomes ChEMBL. 16302820
T1/2 (ADMET) = 3.3 hr Metabolic stability by incubation with human liver microsomes ChEMBL. 16302820
T1/2 (ADMET) = 5.2 hr Half life at late phase in rat at 3 mg/kg, po ChEMBL. 16302820
Tmax (ADMET) = 0.3 hr Time taken to achieve maximum concentration in rat at 3 mg/kg, po ChEMBL. 16302820
Tmax (ADMET) = 0.3 hr Time taken to achieve maximum concentration in dog at 3 mg/kg, po ChEMBL. 16302820
Vdss (ADMET) = 3.3 L/kg Volume of distribution in rat at 3 mg/kg, po ChEMBL. 16302820
Vdss (ADMET) = 6.3 L/kg Volume of distribution in dog at 3 mg/kg, po ChEMBL. 16302820

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.